Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: Additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney

Neuroendocrinology Letters

Volumn 31, Issue SUPPL. 2, 2010, Pages 26-35

  Stiborova, Marie ^a   Moserova, Michaela ^a   Mrazova, Barbora ^a   Kotrbova, Vera ^a   Frei, Eva ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anticancer drug; Cytochrome P450; DNA adduct; Ellipticine; Peroxidase

Indexed keywords

7 HYDROXYELLIPTICINE; 9 HYDROXYELLIPTICINE; ALPHA NAPTHOFLAVONE; ARACHIDONIC ACID; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 3A; DRUG METABOLITE; ELLIPTICINE; FLAVONE; FURAFYLLINE; INDOMETACIN; KETOCONAZOLE; PEROXIDASE; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DNA ADDUCT; DRUG ACTIVATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; KIDNEY MICROSOME; LIVER MICROSOME; LUNG MICROSOME; MALE; MICROSOME; NONHUMAN; OXIDATION; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; ULTRAVIOLET SPECTROSCOPY;

EID: 79952796704     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Aimova D, Svobodova L, Kotrbova V, Mrazova B, Hodek P, Hudecek J, et al. (2007). The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab Dispos. 35: 1926-1934.
2. Arlt VM, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH and Stiborova M (2006). Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitroben-zanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett. 234: 220-231.
3. Auclair C (1987). Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys. 259: 1-14.
4. Boogaard AT, Pandit UK and Koomen GJ (1994). Ring-D modifications of ellipticine. 2. Chlorination of ellipticine via its N-oxide and synthesis and selective acetylation of 5,6,11-trimethyl-5H benzo[B]carbazole.Tetrahedron 50: 4811-4828.
5. Borek-Dohalska L, Frei E and Stiborova M (2004). DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun. 69: 603-615. (Pubitemid 38526511)
6. Bui PH and Hankinson O (2009a). Functional characterization of human cytochrome P450 2S1 using a synthetic gene-expressed protein in Escherichia coli. Mol Pharmacol. 76: 1031-1043.
7. Bui PH, Hsu EL and Hankinson O (2009b). Fatty acid hydroperoxides support cytochrome P450 2S1-mediated bioactivation of benzo[a]pyrene-7,8-dihydrodiol, Mol Pharmacol. 76: 1044-1052.
8. 32P-postlaeling, and GC/MS detection of 4-aminobiphenyl-DANN adducts in human peripheral lung in relation to metabolic activation pathways involving pulmonary N-oxidation, conjugation, and peroxidation. Mutat Res. 378: 97-112. (Pubitemid 27342088)
9. Downie SD, McFadyen MC, PH Rooney PH, Cruickshank ME, Parkin DE, Miller ID, et al. (2005). Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 11: 7369-7735.
10. Eling TE, Thompson DC, Foureman GL, Curtis JF and Hughes MF (1990). Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol. 30: 1-45.
11. Eling TE and Curtis JF (1992). Xenobiotic metabolism by prostaglandin H synthase. Pharm Ther. 53: 261-273.
12. Frei E, Bieler CA, Arlt VM, Wiessler M and Stiborova M (2002). Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol. 64: 289-295. (Pubitemid 34775308)
13. Garbett NC and Graves DE (2004). Extenting nature's leads: the anticancer agent ellipticine. Curr Med Chem Anti-Cancer Agents 4: 149-72. (Pubitemid 38404690)
14. Gasiewicz TA, Kende RS, Rucci G, Whitney B and Willey JJ (1996). Analysis of structural requirements for Ah receptor antagonist activity: Ellipticines, flavones, and related compounds. Biochem Pharmacol. 52: 1787-830.
15. Kotrbova V., Aimova D., Brezinova A., Janouchova K.., Poljakova J., Hodek P., et al. (2006). Cytochromes P450 reconstituted with NADPH:P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. Neuro Endocrinol Lett., 27 (Suppl. 2): 18-20. (Pubitemid 46534329)
16. Kuo PL, Hsu YL, Chang CH and Lin CC (2005a). The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett. 223: 293-301.
17. Kuo PL, Hsu YL, Kuo YC, Chang CH and Lin CC (2005b). The antiproliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anti-Cancer Drugs 16: 789-795.
18. Kuo PL, Kuo YC, Hsu YL, Cho CY and Lin CC (2006). Ellipticine induced apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci. 78: 2550-2557.
19. Martinkova E, Dontenwill M, Frei E and Stiborova M (2009). Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol Lett. 30 (Suppl): 60-66.
20. Martinkova E, Maglott A, Leger, DY, Bonnet D, Stiborova M, Takeda K, et al. (2010). α5β1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 127: 1240-1248.
21. Matsuo M, Yonemitsu N, Zaitsu M, Ishii K, Hamasaki Y, Fukuyama K, et al. (2001). Expression of prostaglandin H synthase-2 in human brain tumors. Acta Neuropathol. 102: 181-187. (Pubitemid 32771667)
22. Moserova M, Kotrbova V, Rupertova M, Naiman K, Hudecek J, Hodek P, et al. (2008). Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. Neuro Endocrinol Lett. 29: 728-732.
23. Ohashi M, Sugikawa E and Nakanishi N (1995). Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn J Cancer Res. 86: 819-829.
24. Omura T and Sato R (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem. 239: 2370-2378.
25. Poljakova J, Dracinsky M, Frei E., Hudecek J and Stiborova M (2006). The effect of pH on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect Czech Chem Commun. 71: 1169-1185. (Pubitemid 44432311)
26. Poljakova J, Frei E, Gomez JE, Aimova D, Eckschlager T, Hrabeta J, et al. (2007). DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett. 252: 270-279. (Pubitemid 46809792)
27. Poljakova J, Eckschlager T, Hrabeta J, Hrebackova J, Smutny S, Frei E, et al. (2009). The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol. 77: 1466-1479.
28. Rendic S and DiCarlo FJ (1997). Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 29: 413-480.
29. Saarikoski T, Rivera SP, Hankinson O and Husgafvel-Pursiainen K (2005). CYP2S1: a short review, Toxicol Appl Pharmacol. 207 (Suppl. 2): 62-69.
30. 5, Pharmacol Ther. 97: 139-152.
31. Shono T, Tofilon PJ, Bruner JM, Owolabi O and Lang FF (2001). Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res. 61: 4375-4381. (Pubitemid 32685762)
32. Soslow RA, Dannenberg AJ, Rush D, Woemer BM, Khan KM, Masferrerer J, etal. (2000). COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645.
33. Stiborova M, Frei E, Schmeiser HH and Anzenbacher P (1991).The role of peroxidases in the activation of chemical carcinogens. Drug Metabol Interact. 9: 177-190.
34. Stiborova M, Bieler CA, Wiessler M and Frei E (2001). The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol. 62: 675-684.
35. 32P-postlabeling. Int J Cancer 107: 885-890. (Pubitemid 37429828)
36. Stiborova M, Stiborova-Rupertova M, Borek-Dohalska L, Wiessler M and Frei E (2003b). Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol. 16: 38-47. (Pubitemid 36139409)
37. 2-oxide. Cancer Res. 64: 8374-8380. (Pubitemid 39496831)
38. Stiborova M, Frei E, Hodek P, Wiessler M and Schmeiser HH (2005a). Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 113: 189-197. (Pubitemid 39628308)
39. Stiborova M, Martinek V, Rydlova H, Koblas T and Hodek P (2005b). Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett. 220: 145-154. (Pubitemid 40568771)
40. Stiborova M, Borek-Dohalska L, Kotrbova V, Kukackova K, Janouchova K, Rupertova M, et al. (2006a). Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - Similarity between human and rat systems. Gen Physiol Biophys. 25: 245-61. (Pubitemid 44857439)
41. 5. Neuro Endocrinol Lett. 27 (Suppl 2): 35-39. (Pubitemid 46534333)
42. Stiborova M, Rupertova M, Schmeiser HH and Frei E (2006c). Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 150: 13-23.
43. Stiborova M, Poljakova J, Ryslava H, Dracinsky M, Eckschlager T and Frei E (2007a). Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer 120: 243-251. (Pubitemid 44956832)
44. Stiborova M, Rupertova M, Aimova D, Ryslava H and Frei E (2007b). Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 236: 50-60. (Pubitemid 46777068)
45. Stiborova M, Arlt VM, Henderson CJ, Wolf CR, Kotrbova V, Moserova M, et al. (2008). Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol. 226: 318-27.
46. Stiborova M, Rupertova M and Frei E (2011). Cytochrome P450-and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta 1814: 175-185.
47. Sugikawa E, Hosoi T, Yazaki N, Gamanuma N, Nakanishi N and Ohashi M (1999). Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res. 19: 3099-3108. (Pubitemid 30042597)
48. Ueng Y-F, Kuwabara T, Chun Y-J and Guengerich FP (1997). Cooperativity in oxidation catalyzed by cytochrome P450 3A4. Biochemistry 36: 370-381. (Pubitemid 27043473)
49. Wiechelman KJ, Braun RD and Fitzpatrick JD (1988). Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 175: 231-237.
50. Wijsmuller WFA, Warner MJ, Koonen Gl, and Pandit UK (1986). Pyridocarbazole alkaloids. Synthesis of olivacine and ellipticine analogues. Heterocycles 24: 1795-1797.